Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36269
Title: | Regional variation in patients and outcomes in the GLOBAL LEADERS trial | Authors: | Gao, Chao Takahashi, Kuniaki Garg, Scot Hara, Hironori Wang, Rutao Kawashima, Hideyuki Ono, Masafumi Montalescot, Gilles Haude, Michael Slagboom, Ton VRANCKX, Pascal Valgimigli, Marco Windecker, Stephan Hamm, Christian Steg, Philippe Gabriel Storey, Robert Van Geuns, Robert-Jan Tao, Ling Onuma, Yoshinobu Serruys, Patrick W. |
Issue Date: | 2021 | Publisher: | ELSEVIER IRELAND LTD | Source: | International journal of cardiology (print), 324 , p. 30 -37 | Abstract: | Background: Despite the overall neutral results of the GLOBAL-LEADERS trial, results from a prespecified subgroup analysis showed that patients from Western Europe had a significantly lower rate of the primary endpoint when treated with ticagrelor monotherapy. Therefore, we aimed to examine the regional disparities in patients' baseline characteristics and their response to ticagrelor monotherapy. Methods: Patients' baseline characteristics and the treatment effects of ticagrelor combined with aspirin for 1 month, followed by ticagrelor monotherapy for 23-months versus 12-months of standard dual antiplatelet therapy (DAPT) were compared according to participating countries. The primary endpoint was a composite endpoint of all-cause death or new Q-wave myocardial infarction at two years. Results: Significant variances in patients' baseline characteristics were found between participating countries. The primary endpoint varied significantly according to the country (P-interaction = 0.027). Patients from France (1.6% versus 5.2%, HR: 0.31, 95%CI: 0.13-0.73) and The Netherlands (2.4% versus 4.8%, HR, 0.50, 95%CI: 0.26-0.94) had lower rates of the primary endpoint when allocated to ticagrelor monotherapy, compared with the standard DAPT regimen. Of the 26 baseline and post-randomization factors explored, variance in the rate of complex PCI between countries was identified as the top contributor to this regional interaction. Conclusions: Patients' baseline characteristics varied between participating countries in the GLOBAL-LEADERS trial. There is a significant regional variance in the treatment effect of ticagrelor monotherapy, which could partly be explained by the differences in complex PCI being performed. (C) 2020 Elsevier B.V. All rights reserved. | Notes: | Serruys, PW (corresponding author), Natl Univ Ireland Galway, Dept Cardiol, Galway, Ireland.; Serruys, PW (corresponding author), Imperial Coll London, NHLI, London, England. patrick.w.j.c.serruys@gmail.com |
Keywords: | Percutaneous coronary intervention; DAPT; Ticagrelor; Aspirin-free;antiplatelet strategies | Document URI: | http://hdl.handle.net/1942/36269 | ISSN: | 0167-5273 | e-ISSN: | 1874-1754 | DOI: | 10.1016/j.ijcard.2020.09.039 | ISI #: | WOS:000612661800005 | Rights: | ©2020 ElsevierB.V. All rights reserved | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0167527320338201-main.pdf Restricted Access | Published version | 1.51 MB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
4
checked on Aug 19, 2024
Page view(s)
26
checked on Jul 20, 2022
Download(s)
2
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.